Literature DB >> 19947346

The allegheny general modification of the Harvard Breast Cosmesis Scale for the retreated breast.

Mark Trombetta1, Thomas B Julian, Yongbok Kim, E Day Werts, David Parda.   

Abstract

The use of brachytherapy--and to a lesser extent, external-beam radiotherapy--in the management of locally recurrent breast cancer following ipsilateral breast tumor recurrence (IBTR) followed by repeat breast-conservation surgery and irradiation is currently an area of intense study. The current cosmetic scoring system is inadequate to score the outcome resulting from retreatment because it does not account for the cosmetic effect of the initial treatment. We propose a modification of the scale for patients who undergo retreatment--the Allegheny General Modification of the Harvard/NSABP/RTOG scoring scale.

Entities:  

Mesh:

Year:  2009        PMID: 19947346

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

1.  Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.

Authors:  Icro Meattini; Sara Cecchini; Cristina Muntoni; Vieri Scotti; Carla De Luca Cardillo; Monica Mangoni; Pierluigi Bonomo; Jacopo Nori; Donato Casella; Roberta Simoncini; Lorenzo Orzalesi; Simonetta Bianchi; Lorenzo Livi
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064

2.  Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.

Authors:  Patrizia Ciammella; Ala Podgornii; Maria Galeandro; Renato Micera; Dafne Ramundo; Tamara Palmieri; Elisabetta Cagni; Cinzia Iotti
Journal:  Radiat Oncol       Date:  2014-04-24       Impact factor: 3.481

3.  5-year results of accelerated partial breast irradiation (APBI) with SBRT (stereotactic body radiation therapy) and exactrac adaptive gating (Novalis®) for very early breast cancer patients: was it all worth it?

Authors:  R Ciérvide; Á Montero; G Potdevin; J García; M G Aranda; B Álvarez; K Rossi; M López; O Hernando; J Valero; E Sánchez; X Chen; R Alonso; P F Letón; C Rubio
Journal:  Clin Transl Oncol       Date:  2021-05-27       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.